No Data
No Data
Express News | Qingsong Co., Ltd.: Guangdong Keprui Biotechnology Co., Ltd. related synthetic biotechnology is still in the early stages of development
Frontier Biology (688221) Quarterly Report Review: The year-on-year sales growth rate of innovative domestic HIV drugs is impressive, and deep academic accumulation helps promote products
Incidents. The company announced its 2024 quarterly report. In Q1 2024, the company achieved sales revenue of 24.65 million yuan, a year-on-year increase of 106.93%, net profit attributable to mother - 55.71 million yuan, net profit from non-return to mother - 62.69 million yuan
Frontier Biology (688221): Deepening academic promotion, Aikenin's 24Q1 grew rapidly year-on-year
Incident: The company achieved operating income of 0.25 million yuan (+106.93%) in the first quarter of 2024, achieving net profit of 60 million yuan to mother and net profit of 60 million yuan after deducting non-return to mother. Aikonin increased 75% year-on-year in the first quarter
Frontier Biotech (688221.SH) announced first-quarter results with a net loss of 55.71 million yuan
Frontier Biotech (688221.SH) disclosed its report for the first quarter of 2024. The company achieved operating revenue during the reporting period...
Frontier Biological-U (688221) Annual Report Review Report: Domestic HIV Innovative Drug Sales Break 100 Million to Fight AIDS, Open Space for Imagination
incident. The company announces 2023 annual report. In 2023, the company achieved sales revenue of 114 million yuan, an increase of 34.82% over the previous year. Aikonin became the first domestically produced new anti-AIDS drug with annual revenue exceeding 100 million yuan. Company 2023
Frontier Biotech (688221.SH) reported 2023 annual results, with a net loss of 329 million yuan, narrowing the year-on-year loss
Frontier Biotech (688221.SH) released its 2023 annual report. The company achieved operating income of 1 during the reporting period...
No Data